exagen diagnostics, inc. is a patient focused, discovery driven, clia-certified, cap-accredited laboratory with a growing menu of proprietary, internally developed tests focusing in the area of rheumatology and autoimmune diseases. committed to personalized medicine, our avise tests are specifically designed to provide objective information to physicians and patients for more accurate, efficient diagnosis and better disease management. for more information on our company, please visit www.exagen.com. for more information on avise testing services, please visit www.avisetest.com.
Company profile
Ticker
XGN
Exchange
Website
CEO
Fortunato Rocca
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
EXAGEN DIAGNOSTICS INC
SEC CIK
XGN stock data
Latest filings (excl ownership)
10-K
2023 FY
Annual report
18 Mar 24
8-K
Exagen Inc. Reports Strong Fourth Quarter and Full-Year 2023 Results
18 Mar 24
8-K
Exagen Inc. Announces Select Preliminary Full-Year 2023 Results and Reaffirms Guidance
8 Jan 24
8-K
Departure of Directors or Certain Officers
11 Dec 23
EFFECT
Notice of effectiveness
30 Nov 23
424B5
Prospectus supplement for primary offering
29 Nov 23
CORRESP
Correspondence with SEC
28 Nov 23
S-3/A
Shelf registration (amended)
27 Nov 23
UPLOAD
Letter from SEC
22 Nov 23
424B5
Prospectus supplement for primary offering
20 Nov 23
Transcripts
XGN
Earnings call transcript
2023 Q4
18 Mar 24
XGN
Earnings call transcript
2023 Q3
13 Nov 23
XGN
Earnings call transcript
2023 Q2
7 Aug 23
XGN
Earnings call transcript
2023 Q1
15 May 23
XGN
Earnings call transcript
2022 Q4
20 Mar 23
XGN
Earnings call transcript
2022 Q3
15 Nov 22
XGN
Earnings call transcript
2022 Q2
6 Aug 22
XGN
Earnings call transcript
2022 Q1
12 May 22
XGN
Earnings call transcript
2021 Q4
23 Mar 22
XGN
Earnings call transcript
2021 Q3
13 Nov 21
Latest ownership filings
4
Kamal Adawi
6 Mar 24
4
JOHN ABALLI
4 Mar 24
4
Kamal Adawi
22 Feb 24
4
JOHN ABALLI
22 Feb 24
SC 13G/A
LYTTON LAURENCE W
14 Feb 24
SC 13G/A
RTW INVESTMENTS, LP
14 Feb 24
SC 13G/A
Stonepine Capital Management, LLC
13 Feb 24
SC 13G/A
TULLIS DICKERSON CAPITAL FOCUS III, L.P.
13 Feb 24
SC 13G/A
WASATCH ADVISORS LP
9 Feb 24
4
Kamal Adawi
8 Feb 24
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 28.65 mm | 28.65 mm | 28.65 mm | 28.65 mm | 28.65 mm | 28.65 mm |
Cash burn (monthly) | 1.01 mm | 3.35 mm | 1.69 mm | 2.68 mm | 969.33 k | 2.38 mm |
Cash used (since last report) | 5.98 mm | 19.94 mm | 10.04 mm | 15.94 mm | 5.76 mm | 14.14 mm |
Cash remaining | 22.67 mm | 8.71 mm | 18.60 mm | 12.71 mm | 22.89 mm | 14.51 mm |
Runway (months of cash) | 22.5 | 2.6 | 11.0 | 4.7 | 23.6 | 6.1 |
Institutional ownership, Q2 2023
71.3% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 32 |
Opened positions | 3 |
Closed positions | 3 |
Increased positions | 9 |
Reduced positions | 5 |
13F shares | Current |
---|---|
Total value | 19.19 bn |
Total shares | 12.28 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
NMSIC Co-Investment Fund | 2.31 mm | $0.00 |
RTW Investments | 1.49 mm | $4.33 bn |
Tullis Dickerson Capital Focus Iii | 1.11 mm | $0.00 |
Stonepine Capital Management | 1.05 mm | $3.04 bn |
Hunt Holdings Limited Partnership | 1.01 mm | $11.76 mm |
Wasatch Advisors | 1.00 mm | $2.90 bn |
Cowen Financial Products | 966.02 k | $2.32 mm |
Cowen And | 842.38 k | $2.44 bn |
SAMG Silvercrest Asset Management | 547.13 k | $1.59 bn |
Vanguard | 490.94 k | $1.42 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
29 Feb 24 | John Aballi | Common Stock | Grant | Acquire A | No | No | 1.91 | 9,804 | 18.73 k | 600,788 |
20 Feb 24 | Kamal Adawi | Common Stock | Grant | Acquire A | No | No | 0 | 75,000 | 0.00 | 256,533 |
20 Feb 24 | John Aballi | Common Stock | Grant | Acquire A | No | No | 0 | 175,000 | 0.00 | 590,984 |
17 Oct 23 | John Aballi | Common Stock | Sell | Dispose S | No | No | 1.7451 | 33,819 | 59.02 k | 415,984 |
31 Aug 23 | John Aballi | Common Stock | Grant | Acquire A | No | No | 2.142 | 9,803 | 21.00 k | 449,803 |
News
Earnings Scheduled For March 18, 2024
18 Mar 24
Earnings Outlook For Exagen
15 Mar 24
Exagen Inc. Announces Select Preliminary Full-Year 2023 Results; Cash Balance Of $36.5M As Of December 31, 2023; Reaffirms FY23 Revenue Guidance Of At Least $50M Vs $50.43M Est.
7 Jan 24
12 Health Care Stocks Moving In Friday's Pre-Market Session
5 Jan 24
12 Health Care Stocks Moving In Thursday's After-Market Session
4 Jan 24
Press releases
Exagen to Announce Fourth Quarter 2023 and Full-Year Financial Results on March 18, 2024
7 Mar 24
Exagen Inc. to Participate in the 2024 BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference
30 Jan 24
Exagen Inc. Announces Select Preliminary Full-Year 2023 Results and Reaffirms Guidance
7 Jan 24